BRIEF published on 12/05/2024 at 13:05, 1 year 6 months ago Theralase Technologies Expands Bladder Cancer Study in Canada Canada Expansion Clinical Study Bladder Cancer Ruvidar Theralase Technologies
PRESS RELEASE published on 12/05/2024 at 13:00, 1 year 6 months ago Theralase(R) Launches New Clinical Study Site in Canada St. Joseph's Healthcare Hamilton joins Theralase®'s clinical investigation for bladder cancer treatment. Theralase® develops light-activated Ruvidar™ drug for BCG-Unresponsive NMIBC CIS patients Theralase® Bladder Cancer BCG-Unresponsive NMIBC CIS RuvidarTM Clinical Study Site
BRIEF published on 11/27/2024 at 23:10, 1 year 6 months ago Theralase Releases 3Q2024 Financial Overview Private Placements R&D Expenses Theralase Financial Overview Revenue And Margins Study II Results
PRESS RELEASE published on 11/27/2024 at 23:05, 1 year 6 months ago Theralase(R) Release’s 3Q2024 Financial Statements Theralase® Technologies Inc. releases unaudited financial statements for the nine-month period ended September 30, 2024, showcasing key financial and operational results. Conference call scheduled for December 4th Conference Call Financial Statements Operational Results Theralase® Technologies Inc. Study II
BRIEF published on 11/15/2024 at 13:05, 1 year 6 months ago Theralase Technologies Concludes Private Placement of $CAN 666,400 Private Placement Warrants Bladder Cancer Theralase Technologies Clinical Stage
PRESS RELEASE published on 11/15/2024 at 13:00, 1 year 6 months ago Theralase(R) Closes Non-Brokered Private Placement Theralase® Technologies Inc. successfully closes non-brokered private placement offering of units for cancer research and development funding Private Placement Offering Drug Development Clinical Study Cancer Research Theralase® Technologies Inc.
BRIEF published on 11/13/2024 at 00:28, 1 year 6 months ago Theralase Technologies Extends Warrant Expiry to 2027 TSX Venture Exchange Warrant Extension Cancer Treatment Theralase Technologies Pharmaceutical Development
PRESS RELEASE published on 11/13/2024 at 00:23, 1 year 6 months ago Theralase(R) Extends Warrants Theralase® Technologies Inc. intends to extend the expiry date of 1,000,000 share purchase warrants from Nov 17, 2024, to Nov 17, 2027. This extension is subject to TSXV approval TSX Venture Exchange Expiry Date Extension Theralase Technologies Inc. Share Purchase Warrants Clinical Stage Pharmaceutical Company
BRIEF published on 10/07/2024 at 13:05, 1 year 8 months ago Theralase Updates on Bladder Cancer Clinical Study FDA Approval Clinical Study Theralase Bladder Cancer Ruvidar
PRESS RELEASE published on 10/07/2024 at 13:00, 1 year 8 months ago Theralase(R) Provides Update on Bladder Cancer Clinical Study Theralase® Technologies Inc. provides update on bladder cancer clinical study for BCG-Unresponsive NMIBC CIS using Ruvidar™ drug activated by TLC-3200 Medical Laser System, achieving positive interim results Clinical Study Theralase® Bladder Cancer RuvidarTM BCG-Unresponsive
Published on 06/10/2026 at 23:05, 1 hour 1 minute ago Faraday Copper Announces Annual General Meeting Voting Results
Published on 06/10/2026 at 14:30, 9 hours 36 minutes ago Agassi Sports Entertainment Signs Tennis Coaching Icon Darren Cahill to Expand Global Coaching, Content and Technology Initiatives
Published on 06/10/2026 at 14:30, 9 hours 36 minutes ago Ondas to Launch LADOS, a Layered Autonomous Defense Operational C2 Layer, at Eurosatory 2026
Published on 06/10/2026 at 13:00, 11 hours 6 minutes ago Galway Metals Reports 5.0 g/t Gold over 10.85 Metres at North Deposit and Continues to Intersect Gold in Northern Extension
Published on 06/10/2026 at 23:56, 10 minutes ago EQS-Adhoc: HUGO BOSS AG: HUGO BOSS informs about unsolicited voluntary takeover offer by Frasers Group plc
Published on 06/10/2026 at 22:05, 2 hours 1 minute ago Ridgewood Infrastructure Acquires Dauntless Air, Premier Provider of Emergency Management Infrastructure
Published on 06/10/2026 at 21:45, 2 hours 21 minutes ago EQS-Adhoc: MAHLE has successfully priced the issuance of additional EUR 200 million notes due 2032 and is launching a partial tender offer for its outstanding notes due 2028
Published on 06/10/2026 at 20:11, 3 hours 55 minutes ago EQS-Adhoc: EDAG Engineering Group AG: Board of Directors resolves on capital measures to strengthen capital base
Published on 06/10/2026 at 18:39, 5 hours 27 minutes ago EQS-Adhoc: Kontron AG: Ad hoc announcement / Ennoconn Corporation intends to launch a mandatory takeover offer to Kontron AG shareholders
Published on 06/10/2026 at 18:29, 5 hours 37 minutes ago ICADE – PR – OUTCOME OF THE COMBINED GENERAL MEETING HELD ON JUNE 10 2026
Published on 06/10/2026 at 17:40, 6 hours 26 minutes ago Report on share repurchases from 3 to 9 June 2026
Published on 06/10/2026 at 07:00, 17 hours 6 minutes ago Acceleration of Museum Studio's international expansion
Published on 06/09/2026 at 19:30, 1 day 4 hours ago MONTHLY INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES
